Cardiac biointerventions: Whatever happened to stem cell and gene therapy?

Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery

Volumn 7, Issue 3, 2012, Pages 173-179

  Rosengart, Todd K ^a   Fallon, Eleanor ^a   Crystal, Ronald G ^b  

^a STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Angiogenesis; Gene therapy; Heart failure; Stem cells; VEGF

Indexed keywords

FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 4; PLACEBO; PLASMID VECTOR; RECOMBINANT PROTEIN; VASCULOTROPIN; VASCULOTROPIN 121; VASCULOTROPIN 165; VASCULOTROPIN C;

ADENOVIRUS; ANGIOGENIC GENE THERAPY; BIOLOGICAL THERAPY; BONE CELL; CLINICAL STUDY; CORONARY ARTERY DISEASE; DRUG EFFICACY; EPICARDIUM; GENE CASSETTE; HEART FAILURE; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEMATOPOIETIC STEM CELL; HUMAN; INTRACORONARY INFUSION; MEDICAL TECHNOLOGY; MYOBLAST; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STEM CELL TRANSPLANTATION; THORACOTOMY; VIRAL GENE DELIVERY SYSTEM;

EID: 84865469024     PISSN: 15569845     EISSN: 15590879     Source Type: Journal    
DOI: 10.1097/IMI.0b013e318265d9f6     Document Type: Review

References (56)

1. Zachary I, Morgan RD. Therapeutic angiogenesis for cardiovascular disease: biological context, challenges, prospects. Heart. 2011;97:181-189.
2. Simons M, Banno RO, Chronos N, et al. Clinical trials in coronary angiogenesis: issues, problems, consensus. Circulation. 2000;102:E73-E86.
3. Yee AI, Rosengart TK. Angiogenesis and gene therapy for the treatment of coronary artery disease. In: Franco K, Verrier ED, eds. Advanced Therapy in Cardiac Surgery. 2nd ed. Hamilton, Ontario: B. C. Decker, Inc; 2003:138-146.
4. Gupta R, Tongers J, Losordo D. Human studies of angiogenic gene therapy. Circulation. 2009;105:724-773.
5. Wollert KC, Drexler H. Cell-based therapy for heart failure. Curr Opin Cardiol. 2006;21:234-239. (Pubitemid 44315089)
6. Allen KB, Dowling RD, Angell WW, et al. Transmyocardial revascularization: 5-year follow-up of a prospective, randomized multicenter trial. Ann Thorac Surg. 2004;77:1228-1234. (Pubitemid 38452353)
7. Schumacher B, Stegmann T, Pecher P. The stimulation of neoangiogenesis in the ischemic human heart by the growth factor FGF: first clinical results. J Cardiovasc Surg. 1998;39:783-789. (Pubitemid 29050348)
8. Stewart DJ, Hilton JD, Arnold JM, et al. Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF (121) versus maximum medical treatment. Gene Ther. 2006;21:1503-1511. (Pubitemid 44574158)
9. Laham R, Sellke FW, Edelman ER, et al. Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery. Circulation. 1999;100:1865-1871.
10. Ruel M, Laham RJ, Parker JA, et al. Long-term effects of surgical angiogenic therapy with fibroblast growth factor 2 protein. J Thorac Cardiovasc Surg. 2002;124:28-34.
11. Symes JF, Losordo DW, Vale PR, et al. Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease. Ann Thorac Surg. 1999;68:830-837. (Pubitemid 29526847)
12. Rosengart TK, Lee LY, Patel SR, et al. Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA. Ann Surg. 1999;230:466-472. (Pubitemid 30191841)
13. Rosengart TK, Lee LY, Patel SR, et al. Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation. 1999;100:468-474. (Pubitemid 29360154)
14. Laham RJ, Chronos NA, Marilyn P, et al. Intracoronary basic fibroblast growth factor (FGF-2) in patients with ischemic heart disease: results of a phase I open-label dose escalation study. J Am Coll Cardiol. 2000;36:2132-2139.
15. Isner JM, Walsh K, Symes J, et al. Arterial gene therapy for therapeutic angiogenesis in patients with peripheral artery disease. Circulation. 1995;91:2687-2692
16. Horvath KA. Clinical studies of TMR with the CO2 laser. J Clin Laser Med Surg. 1997;15:281-285. (Pubitemid 28056000)
17. Hendel RC, Henry TD, Rocha-Singh K, et al. Effect of intracoronary recombinant human vascular endothelial growth factor on myocardial perfusion: evidence for a dose-dependent effect. Circulation. 2000;101:118-121. (Pubitemid 30044247)
18. Simons M, Annex BH, Laham RJ, et al. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2. Double-blind, randomized, controlled clinical trial. Circulation. 2002;105:788-793. (Pubitemid 34174916)
19. Henry TD, Annex BH, McKendall GR, et al; for the VIVA Investigators. The VIVA trial: Vascular Endothelial Growth Factor in Ischemia for Vascular Angiogenesis. Circulation. 2003;107:1359-1365. (Pubitemid 36350732)
20. Henry TD, Grines CL, Watkins MW, et al. Effects of Ad5FGF-4 in patients with angina. An analysis of pooled data from the AGENT-3' and AGENT-4 trials. J Am Coll Cardiol. 2007;50:1038-1046. (Pubitemid 47354223)
21. Lee LY, Patel SR, Hackett NR, et al. Focal angiogen therapy using intramyocardial delivery of an adenovirus vector coding for vascular endothelial growth factor121. Ann Thorac Surg. 2000;69:14-24. (Pubitemid 30078953)
22. Losordo DW, Vale PR, Hendel RC, et al. Phase 1/2 placebo-controlled, double blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation. 2002;105:2012-2018. (Pubitemid 34465261)
23. Kastrup J, Joergensen E, Rück A, et al; for the Euroinject One Group. Direct intra-myocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable angina pectoris Y A randomized double-blind placebo-controlled study. The Euroinject One Trial. J Am Coll Cardiol. 2005;45:982-988. (Pubitemid 40432426)
24. Stewart DJ, Kutryk MJB, Fitchett D, et al. VEGF gene therapy fails to improve perfusion of ischemic myocardium in patients with advanced coronary artery disease: results of the NORTHERN trial. Mol Med. 2009;17:1109-1115.
25. Gyöngyösi M, Khorsand A, Zamini S, et al. NOGA-guidedanalysisof regional myocardial perfusion abnormalities treated with intramyocardial injections of plasmid encoding VEGF A-165 in patients with chronic myocardial ischemia. Subanalysis of the EUROINJECT-ONE multicenter double-blind randomized study. Circulation. 2005;112(suppl I):I-157-I-165. (Pubitemid 41266668)
26. Grines CL, Watkins MW, Mahmarian JJ. A randomized, double-blind, placebo-controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina. J Am Coll Cardiol. 2003;42:1339-1347. (Pubitemid 37267270)
27. Vale PR, Losordo DW, Milliken CE, et al. Left ventricular electromechanical mapping to assess efficacy of phVEGF165 gene transfer for therapeutic angiogenesis in chronic myocardial ischemia. Circulation. 2000;102:965-974. (Pubitemid 30656004)
28. Finniss DG, Kaptchuk TJ, Miller F, et al. Biological, clinical, and ethical advances of placebo effects. Lancet. 2010;375:686-695.
29. Crystal RG, Kaminsky SM, Hackett NR, et al. Double blinded, placebo controlled, randomized gene therapy using surgery for vector delivery. Hum Gene Ther. 2012;27:438-441.
30. Amano H, Hackett NR, Kaner RJ, et al. Alteration of splicing signals in a genomic/cDNA hybrid VEGF gene to modify the ratio of expressed VEGF isoforms enhances safety of angiogenic gene therapy. Mol Ther. 2005;12:716-724. (Pubitemid 41350153)
31. Dekkers W, Boer G. Sham neurosurgery in patients with Parkinson's disease: is it morally acceptable? J Med Ethics. 2001;27:151-156. (Pubitemid 32982844)
32. Moseley JB, O'Malley K, Petersen NJ, et al. A controlled trial of arthroscopic surgery for osteoarthritis of the knee. N Engl J Med. 2002;347:81-88. (Pubitemid 34753477)
33. Arkin LM, Sondhi D, Worgall S, et al. Confronting the issues of therapeutic misconception, enrollment decisions, and personal motives in genetic medicine-based clinical research studies for fatal disorders. Hum Gene Ther. 2005;16:1028-1036. (Pubitemid 41324562)
34. Bostick NA, Sade R, Levine MA, et al. Placebo use in clinical practice: report of the American Medical Association Council on Ethical and Judicial Affairs. J Clin Ethics. 2008;19:58-61.
35. Pelletier MP, Giaid A, Sivaraman S, et al. Angiogenesis and growth factor expression in a model of transmyocardial revascularization. Ann Thorac Surg. 1998;66:12-18. (Pubitemid 28389224)
36. Hare JM, Chaparro SV. Cardiac regeneration and stem cell therapy. Curr Opin Organ Transplant. 2008;13:536-542.
37. Rosenzweig A. Cardiac cell therapy-mixed results from mixed cells. N Engl J Med. 2006;355:1274-1277. (Pubitemid 44427452)
38. Assmus B, Schächinger V, Teupe C, et al. Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation. 2002;106:3009-3017. (Pubitemid 35440281)
39. Siminiak T, Fiszer D, Jerzykowska O, et al. Percutaneous trans-coronaryvenous transplantation of autologous skeletal myoblasts in the treatment of post-infarction myocardial contractility impairment: the POZNAN trial. Eur Heart J. 2005;26:1188-1195. (Pubitemid 40863125)
40. Biagini E, Valgimigli M, Smits PC, et al. Stress and tissue Doppler echocardiographic evidence of effectiveness of myoblast transplantation in patients with ischaemic heart failure. Eur J Heart Fail. 2006;8:641-648. (Pubitemid 44604354)
41. Bolli R, Chugh AR, D'Amario D, et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet. 2011;378:1847-1857.
42. Makkar RR, Smith RR, Cheng K, et al. Intracoronary Cardiosphere-Derived Cells for Heart Regeneration After Myocardial Infarction (CADUCEUS): a prospective, randomised phase 1 trial. Lancet. 2012;379:895-904.
43. Wollert KC, Meyer GP, Lotz J, et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet. 2004;364:141-148. (Pubitemid 38891685)
44. Janssens S, Dubois C, Bogaer J, et al. Autologous bone marrow-derived stemcell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial. Lancet. 2006;367:113-121. (Pubitemid 43077127)
45. Schächinger V, Erbs S, Elsässer A, et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med. 2006;355:1210-1221. (Pubitemid 44427445)
46. Traverse JH, McKenna DH, Harvey K, et al. A controlled trial of bone marrow mononuclear stem cell administration in patients following STelevation myocardial infarction. Am Heart J. 2010;160:428-434.
47. Abdel-Latif A, Bolli R, Tleyjeh IM, et al. Adult bone marrow-derived cells for cardiac repair: a systematic reviewand meta-analysis. Arch Intern Med. 2007;167:989-999.
48. Zhang M, Method D, Poppa V, et al. Cardiomyocyte grafting for cardiac repair: graft cell death and anti-death strategies. J Mol Cell Cardiol. 2001;33:907-921. (Pubitemid 32545326)
49. Segers VFM, Lee RT. Stem-cell therapy for cardiac disease. Nature. 2008;451:937-939.
50. Yau TM, Kim C, Ng D, et al. Increased transplanted cell survival with cellbased angiogenic gene therapy. Ann Thorac Surg. 2005;80:1779-1786. (Pubitemid 41464300)
51. Tang YL, Tang Y, Zhang YC, et al. Improved graft mesenchymal stem cell survival in ischemic heart with a hypoxia-regulated heme oxygenase-1 vector. J Am Coll Cardiol. 2005;46:1339-1350. (Pubitemid 41615559)
52. Retuerto MA, Schalch P, Patejunas G, et al. Angiogenic pre-treatment improves the efficacy of cellular cardiomyoplasty performed with fetal cardiomyocyte implantation. J Thorac Cardiovasc Surg. 2004;127:1041-1049.
53. Retuerto MA, Beckmann JT, Carbray J, et al. Angiogenic pre-treatment enhances myocardial function following cellular cardiomyoplasty with skeletal myoblasts. J Thorac Cardiovasc Surg. 2007;133:478-484.
54. Madden LR, Mortisen DJ, Sussman EM, et al. Proangiogenic scaffolds as functional templates for cardiac tissue engineering. Proc Natl Acad Sci U S A. 2010;107:15211-15216.
55. Guo HD, Cui GH, Wang HJ, et al. Transplantation of marrow derived cardiac stem cells carried in designer self-assembling peptide nanofibers improves cardiac function after myocardial infarction. Biochem Biophys Res Comm. 2010;399:42-48.
56. Miyagawa S, Sawa Y, Sakakida S, et al. Tissue cardiomyoplasty using bioengineered contractile cardiomyocyte sheets to repair damaged myocardium: their integration with recipient myocardium. Transplantation. 2005;80:1586-1595. (Pubitemid 43005870)